| Drug Name |
Linaclotide |
| Drug ID |
BADD_D01291 |
| Description |
Linaclotide is an orally administered, peptide agonist of guanylate cyclase 2C for the treatment of irritable bowel syndrome. Chemically, it is a heterodetic cyclic peptide and consists of fourteen amino acids. The protein sequence is as follows: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr. There are three disulfide bonds which are located between Cys1 and Cys6; between Cys2 and Cys10; and between Cys5 and Cys13. FDA approved on August 30, 2012. |
| Indications and Usage |
Treatment of irritable bowel syndrome (IBS) with constipation and chronic idiopathic constipation. |
| Marketing Status |
approved |
| ATC Code |
A06AX04 |
| DrugBank ID |
DB08890
|
| KEGG ID |
D09355
|
| MeSH ID |
C523483
|
| PubChem ID |
16158208
|
| TTD Drug ID |
D00GNJ
|
| NDC Product Code |
59651-011; 0456-1204; 0456-1203; 14403-0014; 0456-1202; 69766-007; 0456-1206; 12869-110; 63557-0014; 0456-1205; 68625-121; 68625-122; 0456-1201; 32861-0010 |
| UNII |
N0TXR0XR5X
|
| Synonyms |
linaclotide | ASP-0456 | ASP0456 | Linzess | MD-1100 | Linaclotide Acetate | MD-1100 acetate |
